Oncology Collaboration and Licensing Deals 2020-2025
상품코드:1854034
리서치사:Current Partnering
발행일:2025년 10월
페이지 정보:영문 1400+ Pages
라이선스 & 가격 (부가세 별도)
한글목차
본 보고서는 세계 주요 바이오 제약사들이 체결한 종양학 관련 협력 및 라이선싱 계약에 대한 종합적인 이해와 함께 기존에 볼 수 없었던 정보를 제공합니다.
본 보고서는 2020년부터 2025년까지 종양학 관련 3,000건 이상의 계약에 대한 세부 정보를 제공합니다.
주요 장점
2016년 이후 계약 동향
종양학 관련 공동연구 및 라이선싱 계약 체결
벤치마크 분석을 통한 시장 가치 파악
금융 조건(선불금, 마일스톤, 로열티)
기업별, 치료분야별, 기술 유형별 계약 디렉토리
주요 계약금액
가장 활발한 딜 제조업체
각 계약의 자산 내용 및 계약 조건 확인
계약 문서에 대한 액세스 - 계약 구조에 대한 통찰력
실사 - 제안된 계약 조건이 파트너사와의 적합성 평가
수백 시간의 조사 시간 절약
계약서 분석을 통해 다음과 같은 사항에 대한 실사를 할 수 있습니다.
정확히 어떤 권리가 부여되거나 옵션으로 설정되었는가?
계약을 통해 파트너사에 실제로 부여된 것은 무엇인가?
어떤 독점권이 부여되었는가?
거래에 대한 지급 구조는 어떠한가?
판매 및 지급은 어떻게 감사되는가?
거래 기간은 어떻게 되는가?
계약의 핵심 조항들은 어떻게 정의되는가?
지적재산권(IPR)은 어떻게 처리되고 소유되는가?
상업화 책임은 누구에게 있는가?
개발, 공급 및 제조 책임은 누구에게 있는가?
기밀 유지 및 공개는 어떻게 관리되나요?
분쟁은 어떻게 해결되는가?
어떤 조건에서 거래를 종료할 수 있는가?
소유권이 변경되면 어떻게 되는가?
어떤 하위 라이선싱 및 하도급 조항이 합의되었는가?
회사가 고집하는 표준 조항은 무엇인가?
파트너별 또는 거래 유형별로 차이가 있는 것으로 보이는 표준 조항은 무엇인가?
회사가 계약법 적용 관할권으로 고집하는 것은 어디인가?
목차
주요 요약
제1장 서론
제2장 종양학 계약 동향
연차별 제휴 동향
거래 유형별 제휴 동향
산업 부문별 제휴 동향
개발 단계별 제휴 동향
기술 유형별 제휴 동향
치료 적응별 제휴 동향
제3장 종양학 재무 조건 분석
공개 재무 조건
계약 총액
선불금
마일스톤 지불
로열티율
제4장 종양학 : 주요 거래 제조업체와 계약
가장 활발한 계약 기업
가장 활발한 거래 제조업체 리스트
계약금액 상위 계약
제5장 종양학 : 계약 문서 디렉토리
입수 가능한 제휴 계약 문서
제6장 종양학 계약 : 치료 표적별
종양학 계약 : 치료 표적별
계약 디렉토리
계약 디렉토리 : 기업별
계약 디렉토리 : 기술 유형별
계약 유형 정의
Biopharma Research Ltd에 대해
현재 제휴
현재 계약
최근의 파트너십 보고서 타이틀
LSH
영문 목차
영문목차
Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of 3,000+ oncology deals from 2020 to 2025.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2020.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2020
Browse oncology collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.
Oncology Collaboration and Licensing Deals includes:
Trends in oncology dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of oncology deal records covering pharmaceutical and biotechnology
The leading oncology deals by value
Most active oncology licensing dealmakers
In Oncology Collaboration and Licensing Deals, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 - Financial deal terms for oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 - Leading oncology deals and dealmakers
4.1. Introduction
4.2. Most active in oncology partnering
4.3. List of most active dealmakers in oncology
4.4. Top oncology deals by value
Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available
Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by oncology therapeutic target
Deal directory
Deal directory - Oncology deals by company A-Z 2020 to 2025
Deal directory - Oncology deals by technology type 2020 to 2025
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Oncology partnering since 2020
Figure 2: Oncology partnering by deal type since 2020
Figure 3: Oncology partnering by industry sector since 2020
Figure 4: Oncology partnering by stage of development since 2020
Figure 5: Oncology partnering by technology type since 2020
Figure 6: Oncology partnering by indication since 2020
Figure 7: Oncology deals with a headline value
Figure 8: Oncology deals with upfront payment values
Figure 9: Oncology deals with milestone payment
Figure 10: Oncology deals with royalty rates
Figure 11: Active oncology dealmaking activity since 2020
